Drugs / PV-001-DV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03990493 | Apr → Sep 2024 | melanoma | PrimeVax Immuno-Oncology Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03989895 | Apr → Sep 2024 | melanoma | PrimeVax Immuno-Oncology Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PV-001-DV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03989895 ↗ |
| Known as | Dengue Virus-1 #45AZ5 | “PV-001-DV is an attenuated (weakened) strain of dengue virus developed as a potential preventative vaccine for dengue fever by the US Army as Dengue Virus-1 #45AZ5.” NCT03989895 ↗1“Dengue Virus-1 #45AZ5 (PV-001-DV)” NCT03990493 ↗ |
| Modality | Vaccine | “potential preventative vaccine for dengue fever” NCT03989895 ↗ |
| Route | Other | “Intratumoral injection of PV-001-DV (1 injection)” NCT03990493 ↗ |